Sign inJoin waitlistJoin the waitlist

Kelly Chien

Director, CHIP/CCUS Program · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2017–2019
Internal Medicine
University of Texas Southwestern Medical Center
2013–2014
Baylor College of Medicine
2009–2013

Research

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
The Lancet Haematology · 2023 · 226 citations
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
Journal of Clinical Oncology · 2024 · 157 citations
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Review · American Journal of Hematology · 2020 · 152 citations

Guillermo Garcia-Manero
83 papers
Guillermo Bravo
76 papers
Hagop Kantarjian
64 papers
Tapan Kadia
59 papers
KS
Koji Sasaki
55 papers
Courtney DiNardo
50 papers
Naval Daver
50 papers
Elias Jabbour
47 papers
Nicholas Short
46 papers
GB
Gautam Borthakur
45 papers
Rashmi Kanagal-Shamanna
43 papers
Danielle Hammond
42 papers

Clinical trials

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2025–2026
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2029